{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T19:23:55Z","timestamp":1766690635204},"reference-count":37,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"China Natural Sciences Foundation","award":["81471939","81271816"],"award-info":[{"award-number":["81471939","81271816"]}]},{"name":"Major State Basic Research Development Program","award":["2012CB518906"],"award-info":[{"award-number":["2012CB518906"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.vaccine.2016.06.058","type":"journal-article","created":{"date-parts":[[2016,7,2]],"date-time":"2016-07-02T17:41:50Z","timestamp":1467481310000},"page":"4196-4204","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges"],"prefix":"10.1016","volume":"34","author":[{"given":"Qin","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linjuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yali","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zishu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.06.058_b0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1574-6976.2002.tb00601.x","article-title":"An overview of the evolution of enterovirus 71 and its clinical and public health significance","volume":"26","author":"McMinn","year":"2002","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.vaccine.2016.06.058_b0010","doi-asserted-by":"crossref","first-page":"e20005","DOI":"10.1371\/journal.pone.0020005","article-title":"Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.06.058_b0015","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.meegid.2009.05.010","article-title":"Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences","volume":"10","author":"Chan","year":"2010","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.vaccine.2016.06.058_b0020","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJM199909233411302","article-title":"Neurologic complications in children with enterovirus 71 infection","volume":"341","author":"Huang","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.06.058_b0025","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S1474-4422(10)70209-X","article-title":"Clinical features, diagnosis, and management of enterovirus 71","volume":"9","author":"Ooi","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2016.06.058_b0030","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.vaccine.2008.01.058","article-title":"Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge","volume":"26","author":"Chung","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.058_b0035","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1016\/j.vaccine.2013.05.019","article-title":"Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice","volume":"31","author":"Li","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.058_b0040","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.molmed.2004.03.003","article-title":"Vesicular stomatitis virus: re-inventing the bullet","volume":"10","author":"Lichty","year":"2004","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.vaccine.2016.06.058_b0045","doi-asserted-by":"crossref","first-page":"6894","DOI":"10.1016\/j.vaccine.2008.09.082","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses","volume":"26","author":"Geisbert","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.058_b0050","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.058_b0055","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1128\/CVI.00343-07","article-title":"Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein","volume":"15","author":"Liao","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.06.058_b0060","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3201\/eid2102.141649","article-title":"Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses","volume":"21","author":"Marzi","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.058_b0065","doi-asserted-by":"crossref","DOI":"10.1038\/nature14428","article-title":"Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus","author":"Mire","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.06.058_b0070","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine \u2013 preliminary report","author":"Regules","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.06.058_b0075","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1128\/JVI.03246-14","article-title":"A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine","volume":"89","author":"Ryder","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.058_b0080","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1128\/JVI.76.16.8011-8018.2002","article-title":"Identification of two additional translation products from the matrix (M) gene that contribute to vesicular stomatitis virus cytopathology","volume":"76","author":"Jayakar","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.058_b0085","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","article-title":"VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents","volume":"4","author":"Stojdl","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.vaccine.2016.06.058_b0090","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1128\/JVI.03276-13","article-title":"VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications","volume":"88","author":"Tober","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.058_b0095","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1089\/hum.2007.163","article-title":"rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy","volume":"19","author":"Wu","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2016.06.058_b0100","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1093\/nar\/18.20.6069","article-title":"Ligation-independent cloning of PCR products (LIC-PCR)","volume":"18","author":"Aslanidis","year":"1990","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2016.06.058_b0105","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","article-title":"Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines","volume":"169","author":"Whitt","year":"2010","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2016.06.058_b0110","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1128\/JVI.01911-06","article-title":"Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations","volume":"81","author":"Clarke","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.058_b0115","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1016\/j.vaccine.2009.03.006","article-title":"In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation","volume":"27","author":"Johnson","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.058_b0120","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3748\/wjg.v12.i6.921","article-title":"Expression, purification and characterization of enterovirus-71 virus-like particles","volume":"12","author":"Chung","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.vaccine.2016.06.058_b0125","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1128\/JB.91.2.803-812.1966","article-title":"Biophysical studies of vesicular stomatitis virus","volume":"91","author":"McCombs","year":"1966","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2016.06.058_b0130","doi-asserted-by":"crossref","first-page":"7028","DOI":"10.1128\/JVI.00478-06","article-title":"Rapid pathogenesis induced by a vesicular stomatitis virus matrix protein mutant: viral pathogenesis is linked to induction of tumor necrosis factor alpha","volume":"80","author":"Publicover","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.058_b0135","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/JVI.01515-07","article-title":"Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice","volume":"82","author":"Cooper","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.058_b0140","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1016\/j.vaccine.2005.12.047","article-title":"Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71","volume":"24","author":"Chen","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.058_b0145","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0264-410X(01)00385-1","article-title":"Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus","volume":"20","author":"Wu","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.058_b0150","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/1743-422X-8-508","article-title":"Survey of enterovirus infections from hand, foot and mouth disease outbreak in China, 2009","volume":"8","author":"Yang","year":"2011","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2016.06.058_b0155","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S1473-3099(10)70194-8","article-title":"Virology, epidemiology, pathogenesis, and control of enterovirus 71","volume":"10","author":"Solomon","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.058_b0160","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1128\/JVI.02332-10","article-title":"Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus","volume":"85","author":"Ma","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.058_b0165","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1128\/JVI.00365-06","article-title":"Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle","volume":"80","author":"Majid","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.058_b0170","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1006\/viro.1999.0120","article-title":"Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope","volume":"268","author":"Haglund","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.06.058_b0175","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.virusres.2012.11.007","article-title":"Genetically modified VSV(NJ) vector is capable of accommodating a large foreign gene insert and allows high level gene expression","volume":"171","author":"An","year":"2013","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2016.06.058_b0180","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4149\/av_2011_03_227","article-title":"Immunogenicity of a truncated enterovirus 71 VP1 protein fused to a Newcastle disease virus nucleocapsid protein fragment in mice","volume":"55","author":"Ch\u2019ng","year":"2011","journal-title":"Acta Virol"},{"key":"10.1016\/j.vaccine.2016.06.058_b0185","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/0966-842X(94)90336-0","article-title":"The role of TH1 and TH2 subsets in human infectious diseases","volume":"2","author":"Del Prete","year":"1994","journal-title":"Trends Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16305096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16305096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T07:28:59Z","timestamp":1600846139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16305096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":37,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0264410X16305096"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.058","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}